A phase I/II study of arsenic trioxide, bortezomib, and ascorbic acid in relapsed or refractory multiple myeloma

J. R. Berenson; J. V. Matous; D. Ferretti; R. A. Swift; R. A. Mapes; B. Morrison; H. S. Yeh

doi:10.1200/JCO.2006.24.18_SUPPL.7611

A phase I/II study of arsenic trioxide, bortezomib, and ascorbic acid in relapsed or refractory multiple myeloma

J. R. Berenson
, J. V. Matous
, D. Ferretti
, R. A. Swift
, R. A. Mapes
, B. Morrison
, H. S. Yeh

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	24
DOIs	https://doi.org/10.1200/JCO.2006.24.18_SUPPL.7611
State	Published - Jun 20 2006

Disciplines

Medicine and Health Sciences
Oncology
Surgery

Access to Document

10.1200/JCO.2006.24.18_SUPPL.7611License: Unspecified

Cite this

@article{3bc016d7aac4468e92d575214bf1f22d,

title = "A phase I/II study of arsenic trioxide, bortezomib, and ascorbic acid in relapsed or refractory multiple myeloma",

author = "Berenson, \{J. R.\} and Matous, \{J. V.\} and D. Ferretti and Swift, \{R. A.\} and Mapes, \{R. A.\} and B. Morrison and Yeh, \{H. S.\}",

note = "7611 Background: The combination of arsenic trioxide (ATO) and bortezomib (B) has shown synergistic anti-tumor activity against human multiple myeloma (MM) cells in preclinical studies, suggesting that this combination may effectively treat patients with MM. In addition, ascorbic acid (AA) can sensitize MM cells to the cytotoxic effects of ATO.",

year = "2006",

month = jun,

day = "20",

doi = "10.1200/JCO.2006.24.18\_SUPPL.7611",

language = "American English",

volume = "24",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - A phase I/II study of arsenic trioxide, bortezomib, and ascorbic acid in relapsed or refractory multiple myeloma

AU - Berenson, J. R.

AU - Matous, J. V.

AU - Ferretti, D.

AU - Swift, R. A.

AU - Mapes, R. A.

AU - Morrison, B.

AU - Yeh, H. S.

N1 - 7611 Background: The combination of arsenic trioxide (ATO) and bortezomib (B) has shown synergistic anti-tumor activity against human multiple myeloma (MM) cells in preclinical studies, suggesting that this combination may effectively treat patients with MM. In addition, ascorbic acid (AA) can sensitize MM cells to the cytotoxic effects of ATO.

PY - 2006/6/20

Y1 - 2006/6/20

UR - https://ascopubs.org/doi/10.1200/jco.2006.24.18_suppl.7611

U2 - 10.1200/JCO.2006.24.18_SUPPL.7611

DO - 10.1200/JCO.2006.24.18_SUPPL.7611

M3 - Article

VL - 24

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

A phase I/II study of arsenic trioxide, bortezomib, and ascorbic acid in relapsed or refractory multiple myeloma

Disciplines

Access to Document

Other files and links

Cite this